Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.79 |
| ▸ | POLB | P06746 | 2/20 | 0.79 |
| ▸ | TP53 | P04637 | 6/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2171108 | 0.89 | MAPT (0.79) | MAPTPOLBTP53LMNANR1H4 | |
| SCHEMBL2172534 | 0.86 | MAPT (0.68) | MAPTPOLBTP53LMNANR1H4 | |
| SCHEMBL2173304 | 0.85 | POLB (0.68) | MAPTPOLBTP53LMNANR1H4 | |
| SCHEMBL2186610 | 0.85 | MAPT (0.72) | MAPTPOLBTP53LMNA | |
| SCHEMBL2542966 | 0.83 | MAPT (0.70) | MAPTPOLBTP53LMNATHRB | |
| SCHEMBL2547296 | 0.82 | MAPT (0.69) | MAPTPOLBTP53LMNANR1H4 | |
| SCHEMBL2542223 | 0.82 | MAPT (0.66) | MAPTPOLBTP53MEN1KMT2A | |
| SCHEMBL2171936 | 0.82 | POLB (0.68) | MAPTPOLBTP53LMNANR1H4 | |
| SCHEMBL2172878 | 0.81 | TP53 (0.68) | MAPTPOLBTP53LMNANR1H4 | |
| SCHEMBL2171100 | 0.81 | MAPT (0.69) | MAPTPOLBTP53THRBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263588-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2011-10-27 | — | — | US | claimed |
| US-20110263588-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263588-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | GRM5, GRM1, GRM3 | MAPT 2044/4885POLB 4360/4885TP53 4565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.